What are the standard rituximab dosing regimens for an adult without significant renal or hepatic impairment for the common indications such as non‑Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and granulomatosis with polyangiitis?

Rituximab Dosing for Common Indications

Rituximab dosing varies significantly by indication, with FDA-approved regimens ranging from 375 mg/m² weekly for 4 weeks in non-Hodgkin lymphoma to 1,000 mg fixed doses separated by 2 weeks in rheumatoid arthritis. 1

Non-Hodgkin Lymphoma (NHL)

Relapsed/Refractory Follicular or Low-Grade NHL

• Standard dose: 375 mg/m² IV once weekly for 4 weeks 1
• This regimen achieves objective response rates of approximately 48% in relapsed/refractory disease 2
• For retreatment: repeat the same 4-week cycle 1

Previously Untreated Follicular NHL

• 375 mg/m² IV on Day 1 of each chemotherapy cycle (up to 8 doses) 1
• Maintenance therapy: After achieving complete or partial response, administer 375 mg/m² as single-agent every 8 weeks for 12 doses, starting 8 weeks after completion of induction 1
• The NCCN guidelines support rituximab maintenance at 375 mg/m² every 12 weeks for 2 years as a Category 1 recommendation 3

Diffuse Large B-Cell Lymphoma (Aggressive NHL)

• 375 mg/m² IV on Day 1 of each CHOP cycle (up to 8 infusions) 1
• This R-CHOP regimen has demonstrated superior 2-year event-free survival (57% vs 38%) and overall survival (70% vs 57%) compared to CHOP alone in elderly patients 2

Chronic Lymphocytic Leukemia (CLL)

The approved CLL regimen differs from NHL due to lower CD20 expression on CLL cells:

• 375 mg/m² IV the day prior to initiating FC chemotherapy (cycle 1) 1
• 500 mg/m² IV on Day 1 of cycles 2-6 (every 28 days) 1

The higher dose of 500 mg/m² for subsequent cycles addresses the lower response rates seen with standard NHL dosing in CLL, where single-agent rituximab at 375 mg/m² achieved response rates of only 23-45% 2, 4. The escalated dose improves efficacy by overcoming lower CD20 antigen density on CLL cells 5.

Rheumatoid Arthritis (RA)

Two 1,000 mg IV infusions separated by 2 weeks 1

• Administer methylprednisolone 100 mg IV (or equivalent) 30 minutes prior to each infusion to reduce infusion reactions 1
• Must be given in combination with methotrexate 1
• Subsequent courses: every 24 weeks or based on clinical evaluation, but not sooner than every 16 weeks 1

Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

Induction Treatment (Adults)

375 mg/m² IV once weekly for 4 weeks 1

• The 2021 ACR/Vasculitis Foundation guidelines conditionally recommend rituximab over cyclophosphamide for remission induction in active, severe GPA/MPA 6
• Administer methylprednisolone 1,000 mg IV daily for 1-3 days, followed by oral prednisone, beginning within 14 days prior to or with rituximab initiation 1
• Alternative regimen: Two 1,000 mg doses separated by 2 weeks (used in some trials, though the weekly regimen is FDA-approved) 6

Follow-Up/Maintenance Treatment (Adults)

Two 500 mg IV infusions separated by 2 weeks, then 500 mg IV every 6 months 1

• If induction was with rituximab: initiate maintenance within 24 weeks after last induction dose, but no sooner than 16 weeks 1
• If induction was with other immunosuppressants: initiate rituximab within 4 weeks of achieving disease control 1

Pediatric Dosing (GPA/MPA)

• Induction: 375 mg/m² IV weekly for 4 weeks (same as adults) 1
• Maintenance: 250 mg/m² IV × 2 doses separated by 2 weeks, then 250 mg/m² every 6 months 1

Key Clinical Considerations

Infusion Administration

• First infusion: Administer slowly over 4-6 hours due to infusion reaction risk 1
• Subsequent infusions: Can be given over 90 minutes if first infusion tolerated 1
• Rapid infusions: Third and subsequent doses may be safely administered over 60 minutes in patients without prior severe reactions 7

Common Pitfalls

1. Don't use NHL dosing for CLL - The 500 mg/m² dose in cycles 2-6 is critical for CLL efficacy 4
2. Don't skip premedication in RA and GPA/MPA - Glucocorticoid premedication significantly reduces infusion reactions 1
3. Maintenance timing matters - In follicular NHL, starting maintenance too early (before 8 weeks) or delaying beyond recommended intervals may affect outcomes 1

Safety Monitoring

• Infusion reactions occur in the majority of patients but are usually mild to moderate flu-like symptoms that decrease with subsequent infusions 2
• Severe infusion reactions occur in approximately 10% of patients, typically with the first infusion 2
• B-cell depletion typically lasts 6 months, with recovery at 9-12 months 2
• Progressive multifocal leukoencephalopathy (PML) is a rare but serious risk, particularly in heavily pretreated patients 8